Glaukos Corporation
GKOS
Classifica tra le azioni
#2084
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Prezzo delle azioni
$166.79
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$9.84B
Variazione (1 giorno)
1.44%
Variazione (1 anno)
109.88%
Paese
US
Scambia Glaukos Corporation (GKOS)
Categoria
Healthcare
Utile per Glaukos Corporation (GKOS)
Utile nel Jun 2026 TTM: $-192.83M
Secondo gli ultimi rapporti finanziari di Glaukos Corporation, gli utili attuali della società sono $-192.83M. Nel 2023, la società ha registrato un utile di $-133.73M, una diminuzione rispetto a agli utili del 2022, che erano di $-98.43M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Glaukos Corporation dal 2012 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-192.83M | 32.44% |
| 2024 | $-145.60M | 8.88% |
| 2023 | $-133.73M | 35.86% |
| 2022 | $-98.43M | 99.79% |
| 2021 | $-49.27M | -62.77% |
| 2020 | $-132.31M | 164.44% |
| 2019 | $-50.04M | 304.56% |
| 2018 | $-12.37M | -1,236,900.00% |
| 2017 | $1.00K | -99.98% |
| 2016 | $4.57M | -111.92% |
| 2015 | $-38.29M | 172.73% |
| 2014 | $-14.04M | -1.28% |
| 2013 | $-14.22M | -35.41% |
| 2012 | $-22.02M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $7.51B | -3,995.08% |
US
|
|
| $5.56B | -2,984.88% |
IE
|
|
| $5.15B | -2,769.67% |
US
|
|
| $3.86B | -2,102.25% |
US
|
|
| - | - |
DE
|
